Dr. Twelves on the Value of the Iniparib Trial Results

Christopher Twelves, MD

Published Online: Friday, April 1, 2011

Print

Email

Christopher Twelves, MD, Professor of Clinical Cancer Pharmacology and Oncology and Head of the Clinical Cancer Research Group at the University of Leeds in the United Kingdom on the Value of the Negative Iniparib Trial Results

View more videos of Christopher Twelves, MD.

Comment(s)

Your comments are valuable to us. Thank you.

Sorry, you must be logged in and registered to post a comment.

Related Articles

Iniparib Fails to Improve Survival as Part of Chemotherapy in Triple-Negative Breast Cancer

The addition of the PARP inhibitor iniparib failed to improve OS or PFS when added to gemcitabine/carboplatin (GC) compared with GC alone in patients with metastatic TNBC.

Attacking the Frontiers of Breast Cancer: A Conversation With Joyce A. O'Shaughnessy, MD

As a child Joyce Ann O'Shaughnessy enjoyed science and her home chemistry set. Still, she didn't give much thought to pursuing the subject beyond the confines of her school - until she faced a tragedy.

Dual Inhibitors Explored in Triple-Negative Tumors

The use of advanced gene analysis techniques in a small group of women with triple-negative metastatic breast cancer has revealed activity in two pathways found in most patients with this subtype.

Bringing the Oncology Community Together

Dr. Twelves on the Value of the Iniparib Trial Results